# EWSR1 as a regulatory target in hepatic stellate cell apoptosis and liver fibrosis therapy

**Authors:** Zhang Shiwan, Luo Guangcheng, Maisarah Abdul Mutalib

PMC · DOI: 10.1016/j.bbrep.2026.102526 · 2026-02-27

## TL;DR

This paper explores EWSR1 as a new target for treating liver fibrosis by influencing hepatic stellate cell behavior and restoring cell death sensitivity.

## Contribution

EWSR1 is proposed as a novel molecular target for liver fibrosis therapy through its regulatory role in HSC activation and apoptosis.

## Key findings

- EWSR1 modulates fibrosis via transcriptional and non-coding RNA mechanisms.
- Inhibiting EWSR1 restores apoptosis in activated hepatic stellate cells.
- EWSR1 integrates TGF-β and oxidative stress pathways in fibrogenesis.

## Abstract

Liver fibrosis is a progressive condition driven by hepatic stellate cell (HSC) activation and resistance to apoptosis, culminating in excessive extracellular matrix (ECM) accumulation and organ dysfunction. Current antifibrotic therapies remain limited, as most target broad pathways such as TGF-β signaling or oxidative stress without addressing upstream regulators. Emerging evidence identifies the RNA-binding protein Ewing Sarcoma Breakpoint Region 1 (EWSR1) as a pivotal modulator of HSC fate. Through transcriptional regulation, non-coding RNA networks, and stress-granule dynamics, EWSR1 integrates TGF-β signaling, oxidative stress responses, and apoptosis resistance. Inhibition of EWSR1 has been reported in experimental models to suppress fibrosis-related gene expression and restore apoptotic sensitivity in activated HSCs, highlighting its therapeutic potential. This review critically synthesizes recent insights into EWSR1 biology, its crosstalk with profibrotic pathways, and its regulatory influence on HSC activation. We further compare EWSR1 with conventional antifibrotic approaches, outline research gaps, and propose directions for translational development. By positioning EWSR1 as a novel molecular node in fibrogenesis, this article underscores its promise as a next-generation therapeutic target for halting or reversing liver fibrosis.

•EWSR1 is identified as a novel regulator in hepatic stellate cell activation.•EWSR1 modulates fibrosis via transcriptional and non-coding RNA mechanisms.•Suppression of EWSR1 restores apoptosis sensitivity in activated HSCs.•Integrates EWSR1 signaling with TGF-β and oxidative stress pathways.•Positions EWSR1 as a potential antifibrotic therapeutic target.

EWSR1 is identified as a novel regulator in hepatic stellate cell activation.

EWSR1 modulates fibrosis via transcriptional and non-coding RNA mechanisms.

Suppression of EWSR1 restores apoptosis sensitivity in activated HSCs.

Integrates EWSR1 signaling with TGF-β and oxidative stress pathways.

Positions EWSR1 as a potential antifibrotic therapeutic target.

## Linked entities

- **Genes:** EWSR1 (EWS RNA binding protein 1) [NCBI Gene 2130], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040]

## Full-text entities

- **Genes:** FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, MIAT (myocardial infarction associated transcript) [NCBI Gene 440823] {aka C22orf35, GOMAFU, LINC00066, NCRNA00066, RNCR2, lncRNA-MIAT}, PRRX1 (paired related homeobox 1) [NCBI Gene 5396] {aka AGOTC, PHOX1, PMX1, PRX-1, PRX1}, TAF15 [NCBI Gene 101711796], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, FUS [NCBI Gene 101716667], SH3BP4 (SH3 domain binding protein 4) [NCBI Gene 23677] {aka BOG25, TTP}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, EWSR1 [NCBI Gene 101697325], ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SUGP1 (SURP and G-patch domain containing 1) [NCBI Gene 57794] {aka F23858, RBP, SF4}, VGLL3 (vestigial like family member 3) [NCBI Gene 389136] {aka VGL-3, VGL3}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PPM1A (protein phosphatase, Mg2+/Mn2+ dependent 1A) [NCBI Gene 5494] {aka PP2C-ALPHA, PP2CA, PP2Calpha}, TIA1 (TIA1 cytotoxic granule associated RNA binding protein) [NCBI Gene 7072] {aka ALS26, TIA-1, WDM}, FLI1 (Fli-1 proto-oncogene, ETS transcription factor) [NCBI Gene 2313] {aka BDPLT21, EWSR2, FLI-1, SIC-1}, MIR29B1 (microRNA 29b-1) [NCBI Gene 407024] {aka MIRN29B1, miR-29b, miRNA29B1, mir-29b-1}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, EIF3A (eukaryotic translation initiation factor 3 subunit A) [NCBI Gene 8661] {aka EIF3, EIF3S10, P167, TIF32, eIF3-p170, eIF3-theta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, SCRG1 (stimulator of chondrogenesis 1) [NCBI Gene 11341] {aka SCRG-1, lincSCRG1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, RBMS3 (RNA binding motif single stranded interacting protein 3) [NCBI Gene 27303], TGFBR2 (transforming growth factor beta receptor 2) [NCBI Gene 7048] {aka AAT3, FAA3, LDS1B, LDS2, LDS2B, MFS2}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, TBP (TATA-box binding protein) [NCBI Gene 6908] {aka GTF2D, GTF2D1, HDL4, SCA17, TBP1, TFIID}, TUG1 (taurine up-regulated 1) [NCBI Gene 55000] {aka LINC00080, NCRNA00080, TI-227H}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072] {aka HBP231, HIF-1, HIP-1, HSPC069, HYPB, KMT3A}, SMAD7 (SMAD family member 7) [NCBI Gene 4092] {aka CRCS3, MADH7, MADH8}, IGF2BP3 (insulin like growth factor 2 mRNA binding protein 3) [NCBI Gene 10643] {aka CT98, IMP-3, IMP3, KOC, KOC1, VICKZ3}, LAP (Laryngeal adductor paralysis) [NCBI Gene 7939], TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, EWSR1 (EWS RNA binding protein 1) [NCBI Gene 2130] {aka EWS, EWS-FLI1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, G3BP1 (G3BP stress granule assembly factor 1) [NCBI Gene 10146] {aka G3BP, HDH-VIII}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, EIF4G1 (eukaryotic translation initiation factor 4 gamma 1) [NCBI Gene 1981] {aka EIF-4G1, EIF4F, EIF4G, EIF4GI, P220, PARK18}, QKI (QKI, KH domain containing RNA binding) [NCBI Gene 9444] {aka Hqk, QK, QK1, QK3, hqkI}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387] {aka CBP, KAT3A, MKHK1, RSTS, RSTS1}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, HOTAIR (HOX transcript antisense RNA) [NCBI Gene 100124700] {aka HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}
- **Diseases:** neuronal dysfunction (MESH:D009461), metabolic disorders (MESH:D008659), carcinogenesis (MESH:D063646), function (MESH:D003291), Chronic liver injury (MESH:D056487), organ dysfunction (MESH:D009102), obesity (MESH:D009765), Liver fibrosis (MESH:D008103), cancer (MESH:D009369), NAFLD (MESH:D065626), alcohol (MESH:D000437), dyslipidemia (MESH:D050171), glioma (MESH:D005910), cardiac fibrosis (MESH:D005355), metabolic syndrome (MESH:D024821), fibrotic diseases (MESH:D004194), neurodegenerative diseases (MESH:D019636), inflammation (MESH:D007249), fibrotic liver disease (MESH:D008107), FTD (MESH:D057180), HCC (MESH:D006528), cardiac injury (MESH:D006331), fibrotic liver (MESH:D017093), hepatic (MESH:D056486), breast cancer (MESH:D001943), alcoholic liver disease (MESH:D008108), insulin resistance (MESH:D007333), Ewing sarcoma (MESH:D012512), viral hepatitis B and C (MESH:D006525), myocardial infarction (MESH:D009203), cardiovascular disease (MESH:D002318), viral hepatitis (MESH:D014777), metastasis (MESH:D009362), ALS (MESH:D000690)
- **Chemicals:** hydroxyl radicals (MESH:D017665), vitamin A (MESH:D014801), vitamin E (MESH:D014810), ROS (MESH:D017382), N-acetylcysteine (MESH:D000111), OH (MESH:C031356), purine (MESH:C030985), lipid (MESH:D008055), H2O2 (MESH:D006861), O2- (MESH:D013481), 6K (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** LX-2 — Homo sapiens (Human), Transformed cell line (CVCL_5792)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966686/full.md

---
Source: https://tomesphere.com/paper/PMC12966686